Development and validation of the Arizona Cognitive Test Battery for Down syndrome
Development and validation of the Arizona Cognitive Test Battery for Down syndrome
复制标题
DOI：
10.1007/s11689-010-9054-3
复制
发表时间：
2010-09-01
影响因子：
4.9
通讯作者：
Nadel, Lynn
中科院分区：
文献类型：
--
作者：
Edgin, Jamie O.;Mason, Gina M.;Nadel, Lynn
对智力残疾患者进行神经认知评估需要一个经过充分验证的测试系统。为了满足这一需求，亚利桑那认知测试组（ACTB）被专门用于评估唐氏综合症（DS）的认知表型。ACTB包括神经心理学评估，选择1)评估一系列技能，2)非语言，以避免将神经心理学评估与语言需求混淆，3)具有适合研究的分布特性，以识别变异的遗传修饰因子，4)对样本内部和样本之间的差异表现出敏感性，5)与大脑功能具有特定的相关性，6)适用于广泛的年龄范围和跨环境。ACTB包括一般认知能力、前额叶、海马和小脑功能测试。这些任务是从剑桥神经心理测试自动化电池（CANTAB）和其他已建立的范例中提取出来的。除了认知测试外，我们还对认知和行为进行基准评估和家长报告评估。在3个地点测试了74名年龄在7-38岁的DS患者和50名年龄在3-8岁的MA匹配对照组。这些组的一个子样本被用于组间比较，包括55名DS患者和36名心理年龄匹配的对照组。ACTB允许低楼层性能水平和参与者损失。地板效应在年龄较小的儿童中更为明显。与ma匹配的样本相比，DS患者在许多ACTB测试中受损，一些区域的能力得以保留，特别是在需要广泛运动协调的测试中。电池测量与父母报告的行为和发展相关。ACTB在各种情况下提供了一致的结果，包括家庭与实验室访问，跨站点，以及具有广泛的社会经济背景和种族差异的个体。ACTB将在一系列结果研究中发挥作用，包括临床试验和识别认知障碍的重要遗传成分。
Neurocognitive assessment in individuals with intellectual disabilities requires a well-validated test battery. To meet this need, the Arizona Cognitive Test Battery (ACTB) has been developed specifically to assess the cognitive phenotype in Down syndrome (DS). The ACTB includes neuropsychological assessments chosen to 1) assess a range of skills, 2) be non-verbal so as to not confound the neuropsychological assessment with language demands, 3) have distributional properties appropriate for research studies to identify genetic modifiers of variation, 4) show sensitivity to within and between sample differences, 5) have specific correlates with brain function, and 6) be applicable to a wide age range and across contexts. The ACTB includes tests of general cognitive ability and prefrontal, hippocampal and cerebellar function. These tasks were drawn from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) and other established paradigms. Alongside the cognitive testing battery we administered benchmark and parent-report assessments of cognition and behavior. Individuals with DS (n = 74, ages 7-38 years) and mental age (MA) matched controls (n = 50, ages 3-8 years) were tested across 3 sites. A subsample of these groups were used for between-group comparisons, including 55 individuals with DS and 36 mental age matched controls. The ACTB allows for low floor performance levels and participant loss. Floor effects were greater in younger children. Individuals with DS were impaired on a number ACTB tests in comparison to a MA-matched sample, with some areas of spared ability, particularly on tests requiring extensive motor coordination. Battery measures correlated with parent report of behavior and development. The ACTB provided consistent results across contexts, including home vs. lab visits, cross-site, and among individuals with a wide range of socio-economic backgrounds and differences in ethnicity. The ACTB will be useful in a range of outcome studies, including clinical trials and the identification of important genetic components of cognitive disability.